A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
ViroPharma
ClinicalTrials.gov Identifier:
NCT00914966
First received: June 3, 2009
Last updated: May 9, 2012
Last verified: June 2011
  Purpose

The objectives of the study are:

  1. To assess the safety and tolerability of escalating doses of CINRYZE.
  2. To assess the effect of an escalating dose algorithm for CINRYZE on HAE attack rates.
  3. To assess the immunogenicity of CINRYZE.

Condition Intervention Phase
Hereditary Angioedema
C1 Esterase Inhibitor Deficiency
Biological: C1 inhibitor (human)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.

Resource links provided by NLM:


Further study details as provided by ViroPharma:

Primary Outcome Measures:
  • Safety will be assessed by recording the incident and severity of adverse events as well as by monitoring vital signs, clinical laboratory tests, C1INH antibody levels, and the frequency and related details of episodes of thrombosis.

Secondary Outcome Measures:
  • Efficacy assessments will include incidents of any HAE attacks as determined by patient reported diary data, use of rescue therapy, hospitalization and/or use of other therapy for treating a HAE attack.

Estimated Enrollment: 20
Study Start Date: July 2009
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: C1 inhibitor (human)
    1500 Units/twice per week 12 weeks; 2000 Units/twice per week 12 weeks; 2500 Units/twice per week 12 weeks
    Other Name: CINRYZE
Detailed Description:

This open-label, multicenter, Phase 4 study will assess escalating doses of CINRYZE as prophylactic therapy to lower the HAE attack rate in subjects who are not adequately controlled at the recommended CINRYZE dosing regimen.

There will be three potential dose escalation steps for 12 week periods each:

Step 1: 1500 Units twice per week Step 2: 2000 Units twice per week Step 3: 2500 Units twice per week

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible for this protocol, subjects must:

  1. Be ≥6 years of age and ≥25 kg body weight
  2. Have a confirmed diagnosis of HAE with a documented history of swelling of the face, extremities, gastrointestinal tract, genitalia, or larynx and a history of at least one of the following:

    • C1 inhibitor (C1 INH) gene mutation
    • C4 level below the lower limit of the reference range
    • C1 inhibitor antigen level below the lower limit of the reference range
    • Functional C1 inhibitor level below the lower limit of the reference range
    • Family history of HAE (i.e., grandparent, parent, sibling)
  3. Have a history of >1.0 HAE attack per month (average) of any severity over the 3 consecutive months prior to screening while receiving the recommended Cinryze dosing of 1000 U every 3 to 4 days via intravenous injection.
  4. If an adult, be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.

OR If a child, have a parent/legal guardian who is willing and able to provide written informed consent for the child to participate in the study (with assent from the child when appropriate).

Exclusion Criteria:

To be eligible for this protocol, subjects must not:

  1. Have, as determined by the investigator and/or the sponsor's medical monitor, any surgical or medical condition that could interfere with the administration of study drug or interpretation of study results.
  2. Have a history of abnormal blood clotting or other coagulopathy.
  3. Be taking prescription anticoagulation medication
  4. Have a history of allergic reaction to Cinryze or other blood products.
  5. Have participated in any other investigational drug study within the past 30 days (other than Cinryze protocols).
  6. Have received any blood products (other than Cinryze) within 60days prior to screening.
  7. Have any of the following laboratory values at screening:

    • Hemoglobin <8 g/dL
    • White blood cell (WBC) count <2 x 109/L or >20 x 109/L
    • Platelet count <50 x 109/L or >400 x 109/L
    • Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.0 x the upper limit of normal
    • Blood urea nitrogen (BUN) and/or creatinine >2.0 x the upper limit of normal
  8. Be pregnant or breastfeeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00914966

Locations
United States, Arizona
Allergy and Immunology Associates
Scottsdale, Arizona, United States, 85251
United States, California
UCLA Medical Center
Los Angeles, California, United States, 90095
Donald S. Levy, M.D.
Orange, California, United States, 92868
United States, Georgia
Family Allergy and Asthma Center
Atlanta, Georgia, United States, 30342
United States, Maryland
Institute for Asthma and Allergy
Wheaton, Maryland, United States, 20902
United States, New York
Winthrop University Hospital
Mineola, New York, United States, 11501
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267
United States, Oregon
Baker Allergy, Asthma and Dermatology Research Center
Lake Oswego, Oregon, United States, 97035
United States, Tennessee
East Tennessee Center for Clinical Research
Knoxville, Tennessee, United States, 37909
United States, Texas
Mark J. Florian, MD, PA
Bryan, Texas, United States, 77802
AARA Research Center
Dallas, Texas, United States, 75231
Allergy and Asthma Research Center
San Antonio, Texas, United States, 78229
United States, Washington
Marycliff Allergy Specialist
Spokane, Washington, United States, 99204
Puget Sound Allergy, Asthma & Immunology
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
ViroPharma
  More Information

No publications provided

Responsible Party: Marc E. Uknis, MD FACS, ViroPharma Incorporated
ClinicalTrials.gov Identifier: NCT00914966     History of Changes
Other Study ID Numbers: 0624-400
Study First Received: June 3, 2009
Last Updated: May 9, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by ViroPharma:
HAE
C1 inhibitor
C1INH

Additional relevant MeSH terms:
Angioedema
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Genetic Diseases, Inborn
Complement C1 Inhibitor Protein
Complement C1 Inactivator Proteins
Complement C1
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013